Abstract: Stent-based delivery of tacrolimus has shown neointimal hyperplasia and restenosis reduction; FK506 is a water insoluble macrolide immunosuppressant. The purpose of this study was to evaluate acute and chronic tissue response to a polymer-free FK506 drug-eluting stent implantation in a porcine coronary artery model. Seventy-eight nonatherosclerotic minipigs underwent successful placement of 134 stents (control n 5 56; FK506 (1.5 lg/mm2) n 5 44; FK506 (2.6 lg/mm2) n 5 34) at 7, 15, 30, 90, or 180 days. Endothelialisation was almost complete at 7 days, complete at 15 days. At 30 and 90 days, mean neointimal thickness, neointimal area, and % stenosis was significantly less for drug-eluting stents compared with controls. At 180 days, histomorphometric values were similar for eluting and control stents. The FK506-eluting stent allows for a complete reendothelialisation at 15 days and favorably moderate neointimal hyperplasia at 30 and 90 days in the porcine coronary model. Because of a possible limited bioavailability of FK506, long-term inhibition of neointimal formation was not sustained at the considered follow-up. _ 2008 Wiley Periodicals, Inc. J Biomed Mater Res 88A: 872–879, 2009

Short-, mid-, and long-term effects of a polymer-free tacrolimus-eluting stent in a porcine coronary model

PRUNOTTO, MARCO;VIGNOLINI, Maria Cristina;GALLONI, Marco Rodolfo
2008-01-01

Abstract

Abstract: Stent-based delivery of tacrolimus has shown neointimal hyperplasia and restenosis reduction; FK506 is a water insoluble macrolide immunosuppressant. The purpose of this study was to evaluate acute and chronic tissue response to a polymer-free FK506 drug-eluting stent implantation in a porcine coronary artery model. Seventy-eight nonatherosclerotic minipigs underwent successful placement of 134 stents (control n 5 56; FK506 (1.5 lg/mm2) n 5 44; FK506 (2.6 lg/mm2) n 5 34) at 7, 15, 30, 90, or 180 days. Endothelialisation was almost complete at 7 days, complete at 15 days. At 30 and 90 days, mean neointimal thickness, neointimal area, and % stenosis was significantly less for drug-eluting stents compared with controls. At 180 days, histomorphometric values were similar for eluting and control stents. The FK506-eluting stent allows for a complete reendothelialisation at 15 days and favorably moderate neointimal hyperplasia at 30 and 90 days in the porcine coronary model. Because of a possible limited bioavailability of FK506, long-term inhibition of neointimal formation was not sustained at the considered follow-up. _ 2008 Wiley Periodicals, Inc. J Biomed Mater Res 88A: 872–879, 2009
2008
88 (A)
872
879
Drug eluthing stent; Coronary artieries
PRUNOTTO M; VIGNOLINI C; LOLLI V; BLACK A; GAGGIANESI S; SANTARELLI A; GALLONI M
File in questo prodotto:
File Dimensione Formato  
Short-, mid- and long-term 2008.pdf.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 494.79 kB
Formato Adobe PDF
494.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/137273
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact